Abstracts Archive - Page 81 of 2607 - ACR Meeting Abstracts

Abstract Number: 0420 • ACR Convergence 2025
Long-term efficacy of intra-articular triamcinolone hexacetonide injections in juvenile idiopathic arthritis patients starting tumor necrosis factor inhibitor therapy: 48 weeks results from a randomized, open-label, blinded-assessor multicenter phase 4 trial – the MyJIA trial
Pernille Büyesen¹, Anna-Birgitte Aga¹, Vibke Lilleby¹, Maiju Pesonen¹, Marite Rygg², Ellen Nordal³, Bjørn Barstad⁴, Karin Tylleskär⁵, Helga Sanner¹, Siri Hetlevik¹, Nina Martine Sande¹, Inge Christoffer Olsen¹, Siri Lillegraven⁶, Espen Haavardsholm⁷, Athimalaipet Ramanan⁸, Oyvind Molberg⁹ and Berit Flatø¹, ¹Oslo University Hospital, Oslo, Norway, ²Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway., Trondheim, Norway, ³University Hospital of North Norway, Tromsø, Nepal, ⁴Stavanger University Hospital, Stavanger, Norway, ⁵Haukeland University Hospital, Bergen, Norway, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁸Bristol Royal Hosp for Children, Bristol, United Kingdom, ⁹Oslo University Hospital, Oslo, Nepal
Background/Purpose: Modern therapies have improved outcomes in patients with JIA, but up to 60% of patients treated with TNF-α inhibitors (TNFi) have persisting disease activity…
Abstract Number: 0379 • ACR Convergence 2025
Do Rheumatoid Arthritis Patients have Residual Fatigue Without Swollen Joints and Laboratory Inflammation? A Multicenter Study
Rosa Maria Morlà Novell¹, Enrique González-Dávila², Beatriz Frade Sosa³, Maria López-Lasanta⁴, Noemí Busquets Pérez⁵, Marta Valls Roc⁶, Meritxell Sallés Lizarzáburu⁷, Georgina Salvador Alarcón⁸, Virginia Ruiz-Esquide⁹, Lola Tobalina Mastre¹⁰, José Gomez-Puerta¹¹ and Raimon Sanmartí⁹, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Departamento de Matemáticas. Universidad de La Laguna, Tenerife, Spain, ³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ⁴Hospital Universitari Vall d´Hebron, Barcelona, Spain, ⁵Hospital de Granollers, Granollers, Spain, ⁶Hospital Universitari Dr Trueta, Girona, Sudan, ⁷Xarxa Sanitària Althaia Manresa, Manresa, Spain, ⁸Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ⁹Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ¹⁰IDIBAPS. Hospital Clinic de Barcelona, Barcelona, ¹¹Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain
Background/Purpose: Residual fatigue highlights an unmet prevalent1 need in rheumatoid arthritis (RA) patients despite achieving remission of disease activity according to activity indices (DAS28).We examine…
Abstract Number: 0414 • ACR Convergence 2025
Predicting JIA-Associated Uveitis Using Tear Fluid Biomarkers: A Prospective Multicenter Study
Mariia Pavlenko¹, Mekibib Altaye², Hermine Brunner³, Margaret Chang⁴, Ashley Cooper⁵, Stefanie Davidson⁶, Alexandra Duell³, Bharti Gangwani⁴, Aimee Hersh⁷, Gary Holland⁸, Carl Langefeld⁹, Melissa Lerman¹⁰, Mindy Lo⁴, Virginia Miraldi Utz³, Sampath Prahalad¹¹, Grant Schulert³, Megan Quinlan-Waters¹², Erin Stahl⁵, Edmund Tsui⁸ and Sheila Angeles-Han¹³, ¹Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Boston Children's Hospital, Boston, MA, ⁵Children's Mercy Kansas City, Kansas City, MO, ⁶Department of Ophthalmology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, Philadelphia, PA, ⁷University of Utah, Salt Lake City, UT, ⁸UCLA Jules Stein Eye Institute and the Department of Ophthalmology, UCLA David Geffen School of Medicine, Los Angeles, ⁹Wake Forest University School of Medicine, Winston Salem, NC, ¹⁰Division of Rheumatology, Children's Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, Philadelphia, PA, ¹¹Emory + Children's Pediatric Institute, Atlanta, GA, ¹²Cincinnati Children's Hospital Medical Center, CCHMC, ¹³Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA) and can lead to vision loss if not detected early. Current clinical…
Abstract Number: 0355 • ACR Convergence 2025
Changes in scanographic bone mineral density in melanoma patients treated with immunotherapy
Soukayna Baddi¹, Suarez Dimitri¹, Alexis Ruet¹, Theo Van Butsel¹, Damiano Cerasuolo¹, Jean-Matthieu L’Orphelin¹ and Anne-Christine Rat², ¹Caen University Hospital, Caen, France, ²Caen University hospital, UMR ¹⁰⁷⁵ Caen normandy university, Caen, France
Background/Purpose: The use of immune checkpoint inhibitors (ICIs) is becoming increasingly important in the management of melanoma. However, although ICIs are associated with various immune-related…
Abstract Number: 0367 • ACR Convergence 2025
Differences in Self-Reported Medication Nonadherence and its Drivers in Young Adults versus Older Adults with Systemic Lupus Erythematosus
Hannah Concannon¹, Kai Sun², Jennifer Rogers³, Megan Clowse⁴, Rachel Randell², Mithu Maheswaranathan⁵, Lisa Criscione-Schreiber⁵, Nathaniel Harris⁶, Amanda Eudy⁷ and Rebecca Sadun², ¹Duke University School of Medicine, Chapel Hill, NC, ²Duke University, Durham, NC, ³Duke, Durham, NC, ⁴Duke University, Chapel Hill, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶Duke University Medical Center, Durham, NC, ⁷Duke University, Raleigh, NC
Background/Purpose: Medication adherence poses a challenge for patients with SLE, especially younger patients, who often experience both more active disease and more intensive treatments than…
Abstract Number: 0364 • ACR Convergence 2025
Group-Based Medical Mistrust and Logistical Factors Influencing Rheumatology Clinical Trial Enrollment: A Single-Center Cross-Sectional Survey
Andreina Martinez Paulino¹, Miles King², Danny Arias Diaz¹, Asma Cheema³ and Muznay Khawaja⁴, ¹Jersey City Medical Center, Jersey City, NJ, ²Albert Einstein College of Medicine, New York, NY, ³Montefiore Einstein , Wakefield Campus, Woodbridge Township, NJ, ⁴Jersey City Medical Center, Hoboken, NJ

Background/Purpose: Clinical trials are the cornerstone of evidence-based rheumatology, yet enrolling and retaining a representative patient cohort remains challenging. While underrepresentation of underserved minorities is…
Abstract Number: 0421 • ACR Convergence 2025
Inflammatory Orbital Diseases: Pediatric Case Series From a Tertiary Care Center
Rasha Elrefai¹, Katherine Williams² and Hannah Bradfield³, ¹Baylor College of Medicine, Houston, TX, ²Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: Orbital inflammatory diseases in the pediatric population present diagnostic and therapeutic challenges due to variable clinical manifestations, limited prospective data, and lack of standardized…
Abstract Number: 0388 • ACR Convergence 2025
A Scoping Review of Outcomes of Adults With Childhood-Onset Systemic Autoimmune Rheumatic Diseases
Michael Moore¹, Kaien Gu², Carol Cooke¹, Annaliese Tisseverasinghe¹ and Lily Lim¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Systemic autoimmune rheumatic diseases (SARD) include systemic lupus erythematous (SLE), idiopathic inflammatory myositis (IIM), systemic sclerosis (SSc), Sjögren syndrome (SS), and systemic vasculitis (SV).…
Abstract Number: 0429 • ACR Convergence 2025
Real-world experience of upadacitinib therapy in difficult-to-treat juvenile idiopathic arthritis: a case series of 24 patients
Xuemei Tang¹, Xiwen Luo², Xiya Luo¹, Mengwei Ding³, Xi Yang², Dawei Liu², Li Xu², Zhiyong Zhang², Yunfei An² and Xiaodong Zhao¹, ¹Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China, Chongqing, China (People's Republic), ²Department of Rheumatology & Immunology, Children’s Hospital of Chongqing Medical University, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China., Chongqing, China (People's Republic), ³Big Data Center for Children’s Medical Care, Children’s Hospital of Chongqing Medical University, Chongqing, China., Chongqing, China (People's Republic)
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic rheumatic disease. Some patients experiencing active disease due to inadequate responses to conventional treatments. Studies have demonstrated…
Abstract Number: 0340 • ACR Convergence 2025
Associations with fragility fractures in a population with inflammatory bowel disease (IBD): An observational study.
Chern Lee Choy¹, Hamzah Amin² and marwan Bukhari³, ¹University Hospitals of Morecambe Bay NHS Foundation Trust, Barrow-In-Furness, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: It is well recognized that inflammatory bowel disease (IBD) is associated with osteoporosis and fragility fractures, likely due to multiple factors, including systemic inflammation,…
Abstract Number: 0305 • ACR Convergence 2025
From Movement to Meaning: Exploring Physical Function in IBM with Actigraphy
Vaidehi Kothari¹, Eaman Alhassan², Kevin Renz Ambrocio¹, Bonny Rockette-Wagner³, Chester V. Oddis¹, Kendrea (Focht) Garand¹ and Rohit Aggarwal⁴, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³University of Pittsburgh, PITTSBURGH, ⁴University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Inclusion body myositis (IBM) is a progressive and severe inflammatory muscle disease that primarily affects adults over 50 years of age. It presents with…
Abstract Number: 0319 • ACR Convergence 2025
Glucagon-like Peptide-1 Receptor Agonists in Management of Knee Osteoarthritis: A Meta-Analysis
Danielle Madison¹, Adriana Morales Rivera², Dylon Collins², Isabel Lam², Daniel Khokhar², Garrett Snyder², Anthony Thompson², Mark Soliman², Daniela Carralero Somoza² and Michael Sabina², ¹Lakeland Regional Medical Center, Lakeland, FL, ²Lakeland Regional Medical Center, Lakeland
Background/Purpose: Knee osteoarthritis (KOA) is a leading cause of disability and the most common rheumatological condition worldwide. Weight management has been recognized as a key…
Abstract Number: 0403 • ACR Convergence 2025
IL-6 as a Predictor of Response to Olokizumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Results of the Phase 2 Clinical Trial
Ekaterina Alexeeva¹, Tatiana Dvoryakovskaya¹, Elena Zholobova², Elizaveta Krekhova³, Valeria Matkava⁴, Rinat Raupov⁵, Daria Bukhanova⁶, Alina Egorova⁶, Sergey Grishin⁶, Mikhail Samsonov⁶, Mikhail Kostik⁷ and Irina Nikishina⁴, ¹National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), Moscow, Russia, ²I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia, ³National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health, Moscow, Russia, ⁴V.A.Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁵H.Turner National Medical Research Center for Childrens Orthopaedics and Trauma Surgery, Saint-Petersburg, Russia, ⁶R-Pharm JSC, Moscow, Russia, ⁷Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia
Background/Purpose: Olokizumab (OKZ) is a direct interleukin-6 (IL-6) inhibitor. IL-6 is an attractive target for the treatment of pJIA. The aim of the study was…
Abstract Number: 0404 • ACR Convergence 2025
Disease Extension in Children with Limited Juvenile Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Eveline Wu¹, Stephen Balevic², Angel Marks³, Manjushri Bhapkar⁴, Baoshan Zhang³, Alex Fist⁴, Melanie Kohlheim⁵, Vincent Del Gaizo⁶, Laine Thomas³ and Laura Schanberg⁷, ¹UNC Chapel Hill, Chapel Hill, NC, ²Department of Pediatrics, Duke University, Durham, ³Department of Biostatistics & Bioinformatics, Duke University, Durham, ⁴Duke Clinical Research Institute, Duke University, Durham, ⁵CARRA, Granville, OH, ⁶Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁷Duke University Medical Center, DURHAM, NC
Background/Purpose: For children with limited juvenile idiopathic arthritis (JIA), defined as ≤4 affected joints and without uveitis, psoriasis, or sacroiliitis at presentation, it is unknown…
Abstract Number: 0031 • ACR Convergence 2025
Meta-Analysis of Trans-Disease Microbial Biomarkers of Protection and Pathogenesis in Autoimmune Conditions: Results from the AMP AIM Consortium
Kevin Bu¹, Rebecca Blank², Alba Boix-Amoros³, Adam Cantor⁴, Jose Scher⁵ and Jose Clemente¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²NYU Langone Health, New York, NY, ³Icahn School of Medicine, New York, NY, ⁴Icahn School of Medicine, New York, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Autoimmune and immune-mediated diseases (AIMDs) affect over 20 million Americans. The sharp increase in prevalence of these disorders over recent decades suggests that factors…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].